21 CFR 601.12 - Changes to an Approved Biologics License Application

What it says

Changes to an approved biologics license application, including manufacturing process, facility, equipment, specification or labeling changes, must be reported to FDA through one of several defined categories, prior approval supplement, changes being effected supplement, or annual report, based on the change's potential to affect the identity, strength, quality, purity or potency of the product.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This provision is the biologics counterpart to 21 CFR 314.70 for conventional drugs, meaning a company manufacturing both drug and biologic products often needs to apply two related but separately governed change-reporting frameworks.
• Because biological products are more sensitive to manufacturing process changes than many small-molecule drugs, a change that might qualify for a lower reporting category in a conventional drug context can require a higher category here.
• Comparability data generated under ICH Q5E is frequently the technical evidence that supports the reporting category chosen for a given manufacturing change under this provision.

What FDA inspectors look for

• Whether manufacturing, facility or process changes implemented at a licensed biologics site were correctly classified and reported through the appropriate supplement or annual report category.
• Whether prior approval supplements requiring FDA approval before implementation were genuinely not implemented until that approval was obtained.
• Whether the comparability data supporting a change's reporting category classification is scientifically adequate for the type of change made.

Related regulations